What Is The Grand Slam Bundle?

Overview

The Grand Slam Bundle groups three research materials, each characterized in a separate body of published work. It ships as three individual vials, two of which are themselves multi-peptide blends.

GLP3-R is retatrutide (LY3437943). Coskun et al. published its discovery-to-clinical-proof-of-concept characterization as a triple glucagon, GIP, and GLP-1 receptor agonist; Urva et al. reported the phase 1b multiple-ascending-dose study; and phase 2 trials in obesity and type 2 diabetes have appeared in NEJM and The Lancet.[1][2][3][4] It remains investigational with no regulatory approval.

GLOW combines GHK-Cu, BPC-157, and TB-500. Pickart and colleagues have reported that GHK-Cu coordinates Cu(II) and modulates broad gene-expression programs, and Maquart et al. reported stimulation of collagen synthesis in fibroblast cultures.[5][6][7] Hsieh et al. associated BPC-157's pro-angiogenic activity with VEGFR2 activation, and the TB-500 fragment carries the actin-binding motif of Thymosin β4.[8][10][11]

The CJC (no DAC) / Ipamorelin vial pairs two growth-hormone secretagogue research peptides that act at different receptors. The modified GRF(1-29) sequence derives from the work of Lance et al. on super-active GRF analogs and Soule et al. on D-Ala2 substitution.[12][13] Ipamorelin was described by Raun et al. as the first selective growth hormone secretagogue, acting at the ghrelin receptor.[17]

No peer-reviewed study has evaluated these three vials together as a bundle. Every citation on this page describes an individual component or blend studied on its own. Investigators should treat the kit as three separate research materials and consult the dedicated GLP3-R, GLOW, and CJC (no DAC) / Ipamorelin entries for complete mechanism, applications, and reference lists.